Semaglutide Injection– Diabetes (recombinant Route)，weight Loss /diabetes Bulk and Pre-filled Pen 5ml : 0.25mg，CAS No.: 910463-68-2

for my website.

Introduction:

Welcome to our website, where we introduce our Semaglutide Injection – Diabetes, a recombinant route product that is a top-quality weight loss and diabetes solution for individuals with this common health condition worldwide. Our product is available in two options, including the bulk and pre-filled pen, providing customers with an easier way of administering the injection.

Semaglutide Injection – Diabetes is designed and manufactured in our state-of-the-art facility located in China. We prioritize the highest quality standards, adhering to global regulations and guidelines to ensure that our customers receive quality, reliable, and safe solutions.

In this product introduction, we discuss the features, benefits, and the reasons you should consider our Semaglutide Injection – Diabetes as your go-to product for diabetes management and weight loss for merchants who may be looking for a product to wholesale to their customers.

Features:

The Semaglutide Injection – Diabetes comes with salient features that make it unique in the market. Our product features include:

- 5ml:0.25mg packaging that makes it easy for users to administer the injection.

- Our Semaglutide Injection – Diabetes is a recombinant route product, making it safer for users to control their insulin needs.

- It is a combination of weight loss and diabetes solutions, providing customers with an overall health benefit to manage their condition with a single product.

Benefits:

The Semaglutide Injection – Diabetes is designed to provide users with numerous benefits towards their diabetes management and weight loss need. The benefits include:

- Weight loss: The product is designed to promote weight loss, helping you manage diabetes complications, including LDL cholesterol levels, blood pressure, and insulin resistance.

- Diabetes management: Semaglutide Injection – Diabetes helps users manage their diabetes by helping reduce their HbA1c levels and enhance insulin secretion required for glucose control.

- Convenient packaging: Our product is available in a pre-filled pen, making it easy for you to administer the injection at your convenience.

- Easy to use: The Semaglutide Injection – Diabetes comes with clear instructions on how to use it, making it user-friendly for all customers.

Reasons to choose Semaglutide Injection – Diabetes:

- High Quality: Our Product is free from contaminants and impurities, making it a reliable solution for diabetes and weight loss management.

- Safe and Effective: Semaglutide Injection – Diabetes is a safe solution for diabetes and weight loss, produced in compliance with global regulations and guidelines.

- Affordable and Accessible: Our product is offered at competitive prices, making it affordable for customers in need of diabetes and weight loss management solutions.

- Customer Service: We pride ourselves on our commitment to providing our customers with excellent service, before and after their purchase.

Conclusion:

Thank you for considering our Semaglutide Injection – Diabetes as your diabetes and weight loss management solution. Please contact us for an inquiry of the product and the precautionary measure required before use. We extend our commitment to quality and service to you, our customer. Choose Semaglutide Injection – Diabetes for quality, safe, effective, and affordable solutions to diabetes and weight loss management today.

DESCRIPTION

SEMAGLUTIDE injection, for subcutaneous use, contains semaglutide, a human GLP-1 receptor agonist (or GLP-1 analog). The peptide backbone is produced by yeast fermentation. The main protraction mechanism of semaglutide is albumin binding, facilitated by modification of position 26 lysine with a hydrophilic spacer and a C18 fatty di-acid. Furthermore, semaglutide is modified in position 8 to provide stabilization against degradation by the enzyme dipeptidyl-peptidase 4 (DPP-4). A minor modification was made in position 34 to ensure the attachment of only one

fatty di-acid. The molecular formula is C187H291N45O59 and the molecular weight is 4113.58 g/mol.

Structural formula:

SEMAGLUTIDE is a sterile, aqueous, clear, colorless solution. Each pre-filled pen contains a 1.5 mL or a 3 mL solution of SEMAGLUTIDE equivalent to 2 mg semaglutide, a 3 mL solution of OZEMPIC® equivalent to 4 mg of semaglutide, or a 3 mL solution of OZEMPIC® equivalent to 8 mg of semaglutide. Each 1 mL of SEMAGLUTIDE solution contains 0.68 mg, 1.34 mg or 2.68 mg of semaglutide and the following inactive ingredients: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14.0 mg; phenol, 5.50 mg; and water for injections. SEMAGLUTIDE has a pH of approximately 7.4. Hydrochloric acid or sodium hydroxide may be added to adjust pH.

Mechanism of Action

Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors. The principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation. Furthermore, semaglutide is stabilized against degradation by the DPP-4 enzyme. Semaglutide reduces blood glucose through a mechanism where it stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner. Thus, when blood glucose is

high, insulin secretion is stimulated, and glucagon secretion is inhibited. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase.

Pharmacodynamics

Semaglutide lowers fasting and postprandial blood glucose and reduces body weight. All pharmacodynamic evaluations were performed after 12 weeks of treatment (including dose escalation) at steady state with semaglutide 1 mg. Fasting and Postprandial Glucose Semaglutide reduces fasting and postprandial glucose concentrations. In patients with type 2 diabetes, treatment with semaglutide 1 mg resulted in reductions in glucose in terms of absolute

change from baseline and relative reduction compared to placebo of 29 mg/dL (22%) for fasting glucose, 74 mg/dL (36%) for 2-hour postprandial glucose, and 30 mg/dL (22%) for mean 24-hour glucose concentration. (see Figure 1).

Insulin Secretion

Both first-and second-phase insulin secretion are increased in patients with type 2 diabetes treated with OZEMPIC® compared with placebo. Glucagon Secretion Semaglutide lowers the fasting and postprandial glucagon concentrations. In patients with type 2 diabetes, treatment with semaglutide resulted in the following relative reductions in glucagon compared to placebo, fasting glucagon (8%), postprandial glucagon response (14-15%), and mean 24 hour glucagon concentration (12%). Glucose dependent insulin and glucagon secretion Semaglutide lowers high blood glucose concentrations by stimulating insulin secretion and lowering glucagon secretion in a glucose-dependent manner. With semaglutide, the insulin secretion rate in patients with type 2 diabetes was similar to that of healthy subjects (see Figure 2).

During induced hypoglycemia, semaglutide did not alter the counter regulatory responses of increased glucagon compared to placebo and did not impair the decrease of C-peptide in patients with type 2 diabetes. Gastric emptying

Semaglutide causes a delay of early postprandial gastric emptying, thereby reducing the rate at which glucose appears in the circulation postprandially. Cardiac electrophysiology (QTc) The effect of semaglutide on cardiac repolarization was tested in a thorough QTc trial. Semaglutide does not prolong QTc intervals at doses up to 1.5 mg at steady-state.

Name: Semaglutide

Semaglutide is a prescription medicine used to treat the symptoms of Type 2 Diabetes Mellitus. Semaglutide may be used alone or with other medications.

Dosage: Injection

Specification

5ml: 0.25mg

Indications

SEMAGLUTIDE is indicated:

as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Semaglutide to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.

Jiuyuan Gene adheres to the concept of "guided by genetic engineering and contributes to human health", bravely innovating and pursuing excellence.

In October 1996, the company took the lead in the domestic development of the white blood cell-boosting special drug-Jilifen (rhG-CSF) and realized its industrialization, breaking the monopoly of the US and Japanese manufacturers and winning the reputation of "China's first injection".

For more than 20 years, Jiuyuan Gene has successively launched Ji Lifen, Ji Pai Lin, Ji Jufen, Yi Zhe Jia, Ji Ou Ting and Bone Youdao series products.

Honor

Leading Enterprise in Zhejiang Province

Genetic engineering new drug research and development technology service sub-platform

The first batch of post-doctoral research workstations in the province

Excellent Industrial Products of Zhejiang Province

Hangzhou Academician Expert Workstation

Top ten high-tech enterprises in Hangzhou

Zhejiang Green Enterprise

What is your advantage compared with your competitors?

(1). Qualified Manufacturer

(2). Reliable Quality Control

(3). Competitive Price

(4). High-Efficiency working (24*7hours)

(5). One-Stop Service

Our Services

1. Good knowledge on different market can meet special requirements.

2. Real manufacturer with our own factory located in China

3. Strong professional technical team ensure to produce the top quality products.

4. Special cost control system ensure to provide the most favorable price.

5. Rich experience on drug.

Why choose us?

• We take pride in producing the best Recombinant Diabetes Injection products and providing excellent service.
• We are adhering to the business philosophy of high requirements to develop the market with quality, occupy the market with a reasonable price and win credibility with considerate service.
• We provide top-quality Recombinant Diabetes Injection products and excellent customer service.
• We look forward to establishing a long-term business relationship with you in the near future.
• Our Chinese factory provides high-quality Recombinant Diabetes Injection products at affordable prices.
• Our company is an expert in providing complete solutions for Semaglutide Injection– Diabetes (recombinant Route)，weight Loss /diabetes Bulk and Pre-filled Pen 5ml : 0.25mg，CAS No.: 910463-68-2, and an innovative enterprise integrating R&D, production and marketing.
• You can count on us for top-grade Recombinant Diabetes Injection products and outstanding customer service.
• Our new technologies are of great significance to the energy saving and emission reduction of enterprises, improving energy utilization and reducing the costs of our Semaglutide Injection– Diabetes (recombinant Route)，weight Loss /diabetes Bulk and Pre-filled Pen 5ml : 0.25mg，CAS No.: 910463-68-2.
• Our company focuses on producing the best Recombinant Diabetes Injection products and providing excellent customer service.
• We constantly listen to and meet the needs of users, and guide and surpass them.

Hot Tags: semaglutide injection– diabetes (recombinant route)，weight loss /diabetes bulk and pre-filled pen 5ml : 0.25mg，cas no.: 910463-68-2, China semaglutide injection– diabetes (recombinant route)，weight loss /diabetes bulk and pre-filled pen 5ml : 0.25mg，cas no.: 910463-68-2 manufacturers, suppliers, factory, Insulin Aspart injection pen 3ml 300units, Dulaglutide injection pre-filled pen, semaglutide injection pen, Insulin degludec injection 3ml : 300units, liraglutide injection 3 ml 18mg, Insulin degludec injection 3ml 300units